News

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the 2025 meeting of the Amercian Academy of Dermatology.

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in another similar study, which had high favorable response rate in the placebo group.

Rebecca Vasquez, M.D., FAAD, said that while there is not enough data to support success stories yet, she has seen firsthand the ways addressing social drivers of health has impacted her patients.

Raising funding for research on social drivers of health may become an obstacle, given recent anti-DEI policies put into place by the federal government, according to Rebecca Vasquez, M.D., FAAD, a speaker at the 2025 American Academy of Dermatology meeting.

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial hypertension market.

Markary, a surgeon at Johns Hopkins, gave safe, vague and polished answers to senators' questions on mifepristone and the cancellation of an FDA vaccine committee meeting.

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

The experimental Healthy Opportunity Pilots (HOP) program reduced Medicaid spending by addressing the social needs of enrollees in 33 counties in North Carolina, according to evaluation results published in JAMA.

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria Hoffmann-Vold, M.D., Ph.D., of Oslo University Hospital and the expert featured on this MHE K-Cast.

Environmental factors like diet and early antibiotic use have an impact on the gut microbiome and can contribute to inflammatory bowel disease (IBD), explained Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital.

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed.

Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history.

Few question the benefits of adopting a universal healthcare data exchange standard but achieving that goal will prove to be difficult.

Facing a variety of financial pressures, health plans need to take a measured approach to identify supplemental benefit strategies that facilitate their success.

The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.

Major Medicaid cuts may be overshadowing work requirements, but they remain a priority for Republicans. Work requirements are “bad health policy,” says Leanne Berge, J.D., CEO of the Community Health Plan of Washington, although they would not have as great an impact as the cuts that have been under discussion.

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research breakthroughs, the drug pipeline, and the Supplemental Oxygen Access Reform (SOAR) Act in an interview with Managed Healthcare Executive.

According to a KFF analysis, in 2020 an estimated 29% of Medicaid enrollees had a mental illness.

Here’s what you missed this week on Managed Healthcare Executive.

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

At what was supposed to be a hearing to discuss PBM reform, some in Congress veered off into discussions about Medicaid and maternal health, and even Elon Musk.

But major cuts to federal for Medicaid are a likely outcome of the $1.5-$2 trillion in spending cuts over the next 10 years that the Republican-backed budget resolution calls for.

Unlike some other spending cuts, Medicaid cuts will have direct impact on people who voted for Republicans in November 2024, according to Leanne Berge, health plan leader